Naive pluripotent stem cell-based models capture FGF-dependent human hypoblast lineage specification.

FGF blastocyst cell fate embryo model human naive pluripotent stem cells hypoblast

Journal

Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472

Informations de publication

Date de publication:
24 May 2024
Historique:
received: 05 12 2023
revised: 13 03 2024
accepted: 07 05 2024
medline: 2 6 2024
pubmed: 2 6 2024
entrez: 1 6 2024
Statut: aheadofprint

Résumé

The hypoblast is an essential extraembryonic tissue set aside within the inner cell mass in the blastocyst. Research with human embryos is challenging. Thus, stem cell models that reproduce hypoblast differentiation provide valuable alternatives. We show here that human naive pluripotent stem cell (PSC) to hypoblast differentiation proceeds via reversion to a transitional ICM-like state from which the hypoblast emerges in concordance with the trajectory in human blastocysts. We identified a window when fibroblast growth factor (FGF) signaling is critical for hypoblast specification. Revisiting FGF signaling in human embryos revealed that inhibition in the early blastocyst suppresses hypoblast formation. In vitro, the induction of hypoblast is synergistically enhanced by limiting trophectoderm and epiblast fates. This finding revises previous reports and establishes a conservation in lineage specification between mice and humans. Overall, this study demonstrates the utility of human naive PSC-based models in elucidating the mechanistic features of early human embryogenesis.

Identifiants

pubmed: 38823388
pii: S1934-5909(24)00180-2
doi: 10.1016/j.stem.2024.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests G.G. is an inventor on a patent relating to human naive pluripotent stem cells filed by the University of Cambridge. S.L. reports non-financial support from Pfizer outside the submitted work.

Auteurs

Anish Dattani (A)

Living Systems Institute, University of Exeter, Exeter, UK; Department of Clinical & Biomedical Sciences, University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.

Elena Corujo-Simon (E)

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Arthur Radley (A)

Living Systems Institute, University of Exeter, Exeter, UK.

Tiam Heydari (T)

Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.

Yasaman Taheriabkenar (Y)

Living Systems Institute, University of Exeter, Exeter, UK.

Francesca Carlisle (F)

Living Systems Institute, University of Exeter, Exeter, UK.

Simeng Lin (S)

Department of Clinical & Biomedical Sciences, University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.

Corin Liddle (C)

Bioimaging Centre, University of Exeter, Exeter, UK.

Jonathan Mill (J)

Department of Clinical & Biomedical Sciences, University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.

Peter W Zandstra (PW)

Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.

Jennifer Nichols (J)

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Ge Guo (G)

Living Systems Institute, University of Exeter, Exeter, UK; Department of Clinical & Biomedical Sciences, University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK. Electronic address: g.guo@exeter.ac.uk.

Classifications MeSH